{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:56:04Z","timestamp":1791442564970,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 22869"],"award-info":[{"award-number":["IG 22869"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104914","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:33:57Z","timestamp":1788971637000},"page":"104914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Ilenia","family":"Migliaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-3489","authenticated-orcid":false,"given":"Giulia","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":false,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Bergqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-9977","authenticated-orcid":false,"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-8658","authenticated-orcid":false,"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-2997","authenticated-orcid":false,"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104914_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104914_bib2","article-title":"CDK4\/6 inhibitors: a focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer","volume":"93","author":"Migliaccio","year":"2021","journal-title":"Cancer Treatment Reviews WB Saunders Ltd"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13578-020-00493-1","article-title":"Thymidine kinase 1 through the ages: a comprehensive review","volume":"10","author":"Bitter","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.breast.2026.104914_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/575647","article-title":"Thymidine kinase 1 upregulation is an early event in breast tumor formation","author":"Alegre","year":"2012","journal-title":"J Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104914_bib5","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1016\/S0021-9258(18)68484-4","article-title":"Regulation of human thymidine kinase during the cell cycle","volume":"263","author":"Sherley","year":"1988","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.breast.2026.104914_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10549-013-2579-x","article-title":"Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial","volume":"139","author":"Bj\u00f6hle","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2026.104914_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bjc.1990.352","article-title":"Thymidine kinase in breast cancer","volume":"62","author":"Robertson","year":"1990","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1016\/j.breast.2026.104914_bib8","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1158\/1078-0432.CCR-21-1562","article-title":"Evaluating serum thymidine kinase 1 in patients with hormone receptor\u2013positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial","volume":"27","author":"Paoletti","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib9","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1038\/s41598-020-61416-1","article-title":"Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer","volume":"10","author":"Larsson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104914_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2019.04.002","article-title":"Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor\u2013positive metastatic breast cancer: analysis of the randomised phase III evaluation of Faslodex versus exemestane Clinical Trial (EFECT)","volume":"114","author":"McCartney","year":"2019","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.breast.2026.104914_bib11","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/MCB.21.14.4684-4699.2001","article-title":"Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis","volume":"21","author":"Ishida","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","article-title":"Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib","volume":"19","author":"Bagegni","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.breast.2026.104914_bib13","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-19-3271","article-title":"Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial","volume":"26","author":"McCartney","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13058-020-01334-2","article-title":"Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy","volume":"22","author":"Cabel","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104914_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2021.12.030","article-title":"Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant","volume":"164","author":"Malorni","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104914_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.001","article-title":"Serum thymidine kinase activity in patients with HR-positive\/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial","volume":"186","author":"Malorni","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104914_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P4-01-22","article-title":"Abstract P4-01-22: serum thymidine kinase as a biomarker for response beyond progression in first-line CDK 4\/6 inhibitors: insights from the randomized phase II MAINTAIN trial","volume":"31","author":"Sacks","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2026.104914_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2046-4053-2-71","article-title":"Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework","volume":"2","author":"Huguet","year":"2013","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.breast.2026.104914_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/1354750X.2023.2168063","article-title":"Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)","volume":"28","author":"Bergqvist","year":"2023","journal-title":"Biomarkers"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104914_bib26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2024.42.16_suppl.1028","article-title":"Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM\/2014-12 FLIPPER trial","volume":"42","author":"Albanell","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104914_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116817","volume":"242","author":"Guerrero-Zotano","year":"2026","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10549-025-07879-0","article-title":"Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4\/6 and aromatase inhibitors","volume":"216","author":"Brown","year":"2026","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41523-022-00399-w","article-title":"A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis","volume":"8","author":"Krishnamurthy","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5_Supplement","key":"10.1016\/j.breast.2026.104914_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P5-02-27","article-title":"Abstract P5-02-27: serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial","volume":"83","author":"McCartney","year":"2023","journal-title":"Cancer Res"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104914_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P2-07-25","article-title":"Abstract P2-07-25: thymidine kinase activity as a prognostic and predictive biomarker in the phase II PACE trial of CDK4\/6 inhibition beyond progression","volume":"31","author":"Nader-Marta","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104914_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P5-13-22","article-title":"Abstract P5-13-22: serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)","volume":"82","author":"O'Sullivan","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104914_bib33","first-page":"10","article-title":"47P serum thymidine kinase activity in older patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib and letrozole in the RibOB trial","author":"Van Houdt","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.breast.2026.104914_bib34","article-title":"Real-World plasma thymidine kinase activity in high-risk and metastatic hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative breast cancer treated with cyclin-dependent kinase 4\/6 inhibitors","author":"O'Connor","year":"2026","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104914_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.breast.2026.104914_bib24","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/annonc\/mdy214","article-title":"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial","volume":"29","author":"Malorni","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104914_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104644","article-title":"90P effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+\/HER2\u2212 metastatic breast cancer (mBC)","volume":"10","author":"Schmid","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104914_bib30","first-page":"10","article-title":"52P dynamics of ctDNA and serum thymidine kinase activity in patients with ER+\/HER2- metastatic breast cancer receiving abemaciclib vs palbociclib or ribociclib: early results of the TIRESIAS trial","author":"Anichini","year":"2025","journal-title":"ESMO Open"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:48:27Z","timestamp":1791442107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"alternative-id":["S0960977626002249"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104914","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104914"}}